Your browser doesn't support javascript.
loading
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms.
Loghavi, Sanam; Kanagal-Shamanna, Rashmi; Khoury, Joseph D; Medeiros, L Jeffrey; Naresh, Kikkeri N; Nejati, Reza; Patnaik, Mrinal M.
Afiliação
  • Loghavi S; Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas. Electronic address: Sloghavi@mdanderson.org.
  • Kanagal-Shamanna R; Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas.
  • Khoury JD; Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Medeiros LJ; Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas.
  • Naresh KN; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, DC; Section of Pathology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC.
  • Nejati R; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Patnaik MM; Division of Hematology, Department of Medicine, Mayo Clinic, Minnesota.
Mod Pathol ; 37(2): 100397, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38043791
In this manuscript, we review myeloid neoplasms in the fifth edition of the World Health Organization classification of hematolymphoid tumors (WHO-HEM5), focusing on changes from the revised fourth edition (WHO-HEM4R). Disease types and subtypes have expanded compared with WHO-HEM4R, mainly because of the expansion in genomic knowledge of these diseases. The revised classification is based on a multidisciplinary approach including input from a large body of pathologists, clinicians, and geneticists. The revised classification follows a hierarchical structure allowing usage of family (class)-level definitions where the defining diagnostic criteria are partially met or a complete investigational workup has not been possible. Overall, the WHO-HEM5 revisions to the classification of myeloid neoplasms include major updates and revisions with increased emphasis on genetic and molecular drivers of disease. The most notable changes have been applied to the sections of acute myeloid leukemia and myelodysplastic neoplasms (previously referred to as myelodysplastic syndrome) with incorporation of novel, disease-defining genetic changes. In this review we focus on highlighting the updates in the classification of myeloid neoplasms, providing a comparison with WHO-HEM4R, and offering guidance on how the new classification can be applied to the diagnosis of myeloid neoplasms in routine practice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Neoplasias Hematológicas / Transtornos Mieloproliferativos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Neoplasias Hematológicas / Transtornos Mieloproliferativos Idioma: En Ano de publicação: 2024 Tipo de documento: Article